Stockwinners Market Radar for January 18, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:26 EST Cathie Wood's ARK Investment sold 212K shares of DraftKings today

21:25 EST Cathie Wood's ARK Investment bought 528K shares of Recursion Pharmaceuticals

19:50 EST China Liberal Education Holdings Ltd trading halted, news pending

18:47 EST Targa Resources to recommend to board increasing dividend to 75c per share - Targa Resources said that, for 1Q24, it intends to recommend to its Board of Directors an increase to its common dividend to 75c per common share or $3.00 per common share annualized. The recommended common dividend per share increase, if approved, would be effective for the first quarter of 2024 and payable in May 2024.

18:33 EST Airbnb CEO sells $11.0M in common stock - In a regulatory filing, Airbnb disclosed that its CEO Brian Chesky sold 82.0K shares of common stock on January 16th in a total transaction size of $11.0M.

18:11 EST Bright Scholar announces management changes - Bright Scholar Education Holdings announced changes in its management. The Company received a letter of resignation dated January 3rd from Hongru Zhou, notifying the Company of his resignation as the CEO of the Company for personal reasons not resulting from any disagreement with the Company, its management, board of directors or any committee of the Board, on any matter relating to the Company's operations, policies or practice. The Board has accepted Zhou's resignation on January 18, effective from the same date. Zhou will continue to serve as the chairperson of the Board of the Company. The Board has appointed Ruolei Niu as the CEO of the Company, who previously served as the Company's CFO, effective from January 18. The Board has also appointed Hui Zhang, who previously served as the financial director of the Company, as its CFO, effective from the same date. Ruolei Niu served as the CFO of the Company from February 2023 to January 2024. Niu served as the vice general manager of Country Garden Venture Capital from February 2022 to February 2023. Prior to that, Niu had also served as the founder, general manager, co-chief investment officer and responsible officer at CG Partners Asset Management from 2015 to 2022, and the executive director, fund manager and responsible officer at China Merchants Fund Management from 2010 to 2015.

17:55 EST Bowen Acquisition Corp trading halted, news pending

17:33 EST Meta's Zuckerberg says buying 350K Nvidia H100 GPUs by 2024-end - Meta's (META) Mark Zuckerberg plans on acquiring 350,000 NVIDIA (NVDA) H100 graphics cards. On Thursday, Mark Zuckerberg, CEO of Meta (META) said in a blog post to his Instagram account: "Some updates on our AI efforts. Our long term vision is to build general intelligence, open source it responsibly, and make it widely available so everyone can benefit. We're bringing our two major AI research efforts (FAIR and GenAI) closer together to support this. We're currently training our next-gen model Llama 3, and we're building massive compute infrastructure to support our future roadmap, including 350k H100s by the end of this year -- and overall almost 600k H100s equivalents of compute if you include other GPUs. Also really excited about our progress building new AI-centric computing devices like Ray Ban Meta smart glasses. Lots more to come soon." Reference Link

17:01 EST AxoGen announces results from REPOSE clinical study - Axogen announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale. Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group.

16:53 EST Interactive Brokers CIO sells $2.51M in common stock - In a regulatory filing, Interactive Brokers disclosed that its CIO Thomas Frank sold 28.3K shares of common stock on January 16th as part of an option expiry in a total transaction size of $2.51M.

16:40 EST Centene subsidiary selected by New Hampshire DHHS - Centene announced that its subsidiary, NH Healthy Families, one of the largest Medicaid health plans in New Hampshire, has been selected by the New Hampshire Department of Health and Human Services, or DHHS, to provide physical health, behavioral health and pharmacy services for New Hampshire's Medicaid managed care program, known as Medicaid Care Management, or MCM. The program supports approximately 178,000 MCM members, including pregnant women, children, non-elderly, non-disabled adults under the age of 65 and individuals who are aged, blind or disabled. The MCM contract was approved by Governor Chris Sununu and the Executive Council, in coordination with DHHS, and will be effective from September 1, 2024 through August 31, 2029.

16:39 EST Consolidated Edison raises quarterly dividend to 83c from 81c per share - Consolidated Edison declared a quarterly dividend of 83c a share on its common stock, payable March 15 to stockholders of record as of February 14, an annualized increase of 8c over the previous annualized dividend of $3.24 a share.

16:35 EST F.N.B. completes sale of $650M of investment securities - As part of its ongoing proactive balance sheet management strategy, FNB completed the sale of approximately $650M of available-for-sale investment securities in mid-December and transferred $355M of indirect auto loans to held-for-sale. The cumulative impact of these balance sheet actions has a tangible book value earn back period of less than one year, versus an earn back of five years for a stock buyback, an alternative use of capital, and earnings accretion that is significantly higher.

16:34 EST EPO grants GH Research patent with claims directed to 5-MeO-DMT for MDD/TRD - GH Research announced that it recently received a communication from the European Patent Office or EPO, that it has been granted a patent with claims directed to mebufotenin or 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder MDD and treatment-resistant forms of MDD, such as treatment-resistant depression or TRD. The newly granted patent, EP3927337, which will have an effective date of February 14 and an expiry date of no earlier than 2040, is expected to cover all mebufotenin 5-MeO-DM and mebufotenin salt products for use in the treatment of MDD and TRD, including but not limited to products administered through pulmonary inhalation, intravenous and intranasal routes. It is therefore expected to effectively fortify the company's position at the forefront of novel rapid-acting antidepressant treatments. Similar patent applications are pending on behalf of the company in the US and in over thirty other jurisdictions, aiming to provide broad coverage in all key geographies for the therapeutic use of mebufotenin in MDD and TRD...Theis Terwey, CEO and Co-founder of GH Research said: "We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments. Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP..."

16:32 EST Wendy's says Kirk Tanner to succeed Todd Penegor as President & CEO - The Wendy's Company (WEN) announced that its Board of Directors has appointed Kirk Tanner as Wendy's President and CEO, effective February 5. Tanner will succeed Todd Penegor, who will depart from the company and Board in February after serving in senior leadership positions at Wendy's for more than a decade. Tanner has also been elected to serve on the Wendy's Board of Directors. Tanner most recently served as CEO of North American Beverages at PepsiCo (PEP), and joins Wendy's with more than 30 years of experience across beverages, snacks and foodservice.

16:28 EST Mesa Air enters new terms with United Airlines, gives update on CRJ-900 program - Mesa Air (MESA) announced agreements with United Airlines (UAL) to amend its capacity purchase agreement and certain credit agreements between the parties to significantly improve Mesa's operating income and liquidity over the next twelve months. The company also issued an update on its efforts to sell excess CRJ-900 assets to reduce debt and bolster liquidity. On January 11, Mesa entered into an agreement with United that significantly increased the block-hour rate under its CPA, covering the period from October 1, 2023 to December 31. The company expects this increase will provide Mesa approximately $63.5M in incremental revenue over the next twelve months and bolster liquidity. Mesa and United also agreed to amend certain notice requirements related to eight CRJ-900 aircraft covered under the CPA and to extend United's waiver of utilization requirements for aircraft under contract until June 30. In conjunction with the CPA amendment, United agreed to reduce the outstanding balance on the revolving credit facility by $2.1M and relieve the full $10.5M principal amount of the bridge loan it previously issued to Mesa, in exchange for Mesa's investment in privately-held Heart Aerospace. Mesa originally purchased the stake in Heart for $5M and following this transaction, Mesa continues to hold 222,222 unvested warrants, each struck at a value of $0.01, in Heart. As a result of the bridge loan elimination, Mesa's equity investment in Archer Aviation (ACHR) is released as collateral. Mesa currently owns 2.27M vested shares and 1.17M unvested warrants, each struck at a value of $0.01, in Archer common stock. During the September quarter, Mesa closed on the sale of three of the seven CRJ-900 NextGen aircraft that it previously agreed to sell to a third party. Subsequent to quarter end, Mesa closed on the sale of the remaining four aircraft. The sales of these seven CRJ-900s generated gross proceeds of approximately $71.2M, resulting in the elimination of approximately $63.2M of debt principal, approximately $27.3M of which was reflected in Mesa's total debt balance as of September 30, 2023, and creating approximately $8M in additional liquidity. Using proceeds from the sales of the seven CRJ-900 NextGen aircraft, Mesa retired approximately $59M outstanding on its loan from Export Development Bank of Canada and repaid $4.2M of its junior note to MHI RJ Aviation Group, which together financed those assets. As a result of the partial repayment of the MHIRJ junior note, Mesa met the conditions for MHIRJ to forgive the remaining approximately $5M outstanding on the note. During the fourth quarter, Mesa also closed on the sales of three of seven CRJ-900s aircraft that it previously agreed to sell to a third party. Subsequent to quarter end, Mesa closed on the sale of the final four aircraft under this agreement. The sales of these seven CRJ-900s generated gross proceeds of approximately $21M, resulting in the elimination of approximately $10.8M in debt principal, approximately $5.3M of which was reflected in Mesa's total debt balance as of September 30, 2023, and creating $10.2M in additional liquidity. Subsequent to quarter end, Mesa also entered into several new asset sale agreements to sell 15 CRJ-900 airframes and 65 CF34-8C5 engines for total proceeds of $105.8M. These transactions are anticipated to eliminate approximately $89.8M of debt and finance lease buyout obligations, creating approximately $16M of additional liquidity and meaningfully reducing the company's go-forward cash interest expense, with the majority expected to close by March 2024. Mesa remains engaged in additional efforts to market and sell excess CRJ-900 assets. During fiscal full-year 2023, Mesa had a peak total debt balance of $701.3M at the end of Q1 2023. Over the subsequent three quarters, Mesa has reduced total debt by $161.6M to an estimated $539.7M balance at the end of Q4 2023 as a result of CRJ-related asset sales and scheduled principal repayments. For fiscal full-year 2024, the company expects the completion of CRJ-related asset sale agreements currently entered into and scheduled principal repayments through Q4 will reduce total debt by an additional $225.4M, for a projected total debt balance of $310.3M at fiscal year end. Of the $310.3M debt balance, $158.8M is attributable to E-175 aircraft that are pass-through to United Airlines under Mesa's CPA; $110.7M is U.S. Treasury debt collateralized primarily by 31 CRJ-900s; $35.6M is United Airlines debt collateralized with aircraft parts; and $9.2M is attributable to future lease obligations.

16:21 EST Bioventus amends credit, guaranty agreement - Bioventus announced that it has entered into an amendment to the credit and guaranty agreement, between the company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, July 11, 2022 and March 31, 2023. Among other items, the Amendment provides for additional financial covenant relief through Q3 of 2025, including the company's leverage maintenance covenant and interest coverage ratio. The amended covenant levels are expected to provide the company with greater financial and operational flexibility relative to its operating plan in order to execute on key growth initiatives and enhance profitability. Financial covenant thresholds will revert to existing levels under the credit agreement for all covenants by the Q4 of 2025.

16:18 EST NextCure presents preclinical VSTM-1 data - NextCure announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease, or COPD, at the Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy. VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades. Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins. This immunosuppressive function, combined with the strong expression profile of VSTM-1 on pulmonary myeloid cells and the prominent role of neutrophils as inflammatory mediators of lung immunopathology, makes VSTM-1 a promising novel therapeutic target for COPD. NextCure developed an agonist monoclonal antibody, or mAb, against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease. The agonist antibody has demonstrated activity in vitro, ex vivo and in highly relevant in vivo models. Key findings from the study include: The agonist antibody blocks neutrophil-mediated inflammation and cytokine production associated with tissue damage in vitro and ex vivo. Treatment with the agonist antibody reduces pulmonary pathology and prevents disease in animal models, including a highly relevant syngeneic mouse model engineered to express the human VSTM-1 protein. Additional preclinical chronic models of inflammatory disease and relevant, mechanistically based combination studies in COPD and other indications are being planned.

16:16 EST American Coastal names Svetlana Castle as CFO - American Coastal Insurance Corporation announced changes to its executive leadership team. Svetlana Castle, JD, MPA, CPA, has been appointed as the new Chief Financial Officer, effective Monday, January 22, 2024. Ms. Castle will be joining as a member of ACIC's executive team and report directly to ACIC President, B. Bradford Martz. Mr. J. Andy Gray, CPA, has been promoted to the newly created position of Chief Compliance and Risk Officer. Mr. Gray, with extensive experience in tax, accounting, and internal audit, joined the Company in 2017, after the Company's merger with American Coastal Insurance Company, and has held various roles within the organization.

16:12 EST Supermicro jumps 5% to $327.00 after raising Q2 guidance

16:09 EST Avista files multi-year rate plan in Washington - Avista filed a multi-year rate plan with the Washington Utilities and Transportation Commission, or WUTC, that, if approved, would allow the company to recover increased operating and maintenance costs and ongoing investments to infrastructure, technology and more. If approved, new rates would be effective in December and December 2025. If approved, the electric general rate request is designed to increase annual revenue by $77.1M effective in December , and $53.7M effective in December 2025. If approved, the natural gas general rate request is designed to increase annual base revenue by $17.3M effective in December and $4.6M effective in December 2025. The electric and natural gas requests are based on a proposed rate of return of 7.61%, with a common equity ratio of 48.5%, and a 10.4% return on equity.

16:09 EST AST SpaceMobile secures strategic investment from AT&T, Google, Vodafone - AST SpaceMobile (ASTS) announced strategic investment from AT&T (T), Google (GOOGL) and Vodafone (VOD) and aggregate new financing of up to $206.5 million in gross proceeds. In addition to the $155 million strategic investment, the company also plans to draw up to $51.5 million from the company's existing senior-secured credit facility. New investors AT&T and Google, joined by existing investor Vodafone, are at the forefront of wireless innovation, with products and services serving billions of people daily. This significant investment in AST SpaceMobile underscores confidence in the company's technology and leadership position in the emerging space-based cellular direct-to-device market, with the potential to offer connectivity to today's 5.5 billion cellular devices when they are out of coverage.

16:08 EST EPO rules in favor of Exelixis on patent covering Cabometyx - Exelixis announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO). The three-member panel of the Opposition Division rejected all grounds of opposition, thus upholding the patent as granted. The patent at issue, which expires on July 18, 2031, covers tablet formulations of cabozantinib, including the tablet formulation approved as CABOMETYX(R) (cabozantinib) tablets by the European Medicines Agency. The decision is specific to the European patent at issue and is subject to appeal to the EPO Technical Boards of Appeal.

16:02 EST Cambium Networks announces departure of CFO Andrew Bronstein - Cambium announced that Andrew Bronstein, Cambium's CFO, will be leaving the company effective February 2, to pursue an outside opportunity. Cambium is working to find a permanent replacement. In the interim, John Becerril, Cambium's chief accounting officer, will assume the responsibilities as acting CFO. Andrew has agreed to assist in the transition to a new CFO following his departure.

16:00 EST Ikena Oncology Inc trading halted, news pending

15:53 EST Amazon says John Felton taking on new role as SVP and AWS CFO - Doug Herrington posted the following messages shared with Amazon employees: "I want to share with you that John Felton will be taking on a new role as SVP and AWS CFO, reporting to Brian Olsavsky. John has been with Amazon for over 19 years, including the last 12 years within Operations, and we are lucky to have benefited from his many talents within Worldwide Stores. I want to thank him for everything he's done for the Worldwide Operations team. Most recently, John and his teams have led the successful work to regionalize our U.S. network, both improving our delivery speeds for customers and reducing our cost to serve. He leaves our Operations network in a strong place. With John's transition, I'm pleased to share that Udit Madan will take over leading Worldwide Operations. In his 15+ years with Amazon, and most recently as the leader of our global delivery services, Udit has demonstrated a deep customer obsession and a passion for innovation. I'm excited to work even more closely with him as he and the team double down on reinventing ways to further advance our work to improve delivery speeds, widen selection, and lower our cost to serve customers." Reference Link

15:17 EST J.B. Hunt raises quarterly dividend by 2% to 43c per share - The dividend is payable to stockholders of record on February 9, 2024 and will be paid on February 23, 2024.

14:38 EST Berry Corporation sees 2023 production at high end of view 25,300 boe/d - Berry Corporation announced select preliminary full year 2023 production and year-end proved reserves data. The Company also reported that it completed a small scale, all cash bolt-on acquisition at year-end 2023 in line with corporate strategy, while reducing revolver debt in the fourth quarter 2023. ...The Company currently estimates that total production for the full year 2023 will be approximately 25,300 barrels of oil equivalent per day boe/d, with about 93% of the production being oil. The total production estimate is at the high end of the Company's guidance reported in September 2023 and represents an increase of around 200 boe/d compared to the guidance midpoint. The increase was largely related to improved performance of base production. Proved reserves estimates were approximately 103M barrels of oil equivalent at December 31 based on a third-party reserve report and SEC pricing of $77.30 per barrel for crude oil and $3.725 per thousand cubic feet for natural gas. In 2023...Using strong cash flows from production, Berry also reduced the debt outstanding under its revolver by approximately $25M in the fourth quarter of 2023, which includes the impact of the bolt-on acquisition and had total debt at the end of the year of $428M compared to $454M at the end of the third quarter of 2023. Berry's CEO, Fernando Araujo, said, "In 2023, Berry maintained steady production by effectively developing and managing its reservoirs, which we did with less capital than originally planned, and through strategic acquisitions. As a result, we expect to deliver 2023 production at the high end of our guidance..."

14:13 EST Iowa Attorney General Bird sues TikTok for misleading parents - "Iowa Attorney General Brenna Bird sued TikTok for deceiving Iowans, particularly parents, by lying about children's widespread access to inappropriate content on its social-media app. "TikTok has kept parents in the dark," said Attorney General Bird. "It's time we shine a light on TikTok for exposing young children to graphic materials such as sexual content, self-harm, illegal drug use, and worse. TikTok has sneaked past parental blocks by misrepresenting the severity of its content. But no longer. As a mom and prosecutor, I am committed to equipping parents with information to keep their kids safe and to holding TikTok accountable." The lawsuit explains that TikTok:Claims a "12+" rating in Apple's App Store, despite frequent and intense adult content, including: Sexual content and nudity Profanity and crude humorMature and suggestive themes...."Other publicly traded companies in the social media space include: Meta Platforms (META), Snap (SNAP), X(TWTR), Alphabet (GOOG, GOOGL), Spotify (SPOT) and Tencent (TCEHY) and Pinterest (PINS). Reference Link

14:12 EST Walmart says average store manager salary going to $128,000 per year - Walmart said in a statement: "We're simplifying and increasing store manager wages. With this investment and upcoming annual increases, the store manager average salary will go from $117,000 to $128,000 a year. Second, we're redesigning our store manager bonus program. In addition to sales, your store's profit will play a bigger role in calculating your annual bonus. If you hit all targets, your bonus could now be up to 200% of your base salary." Reference Link

14:00 EST GLP-1 drugs helping normalize obesity treatment, ReShape CEO tells The Fly

14:00 EST ReShape CEO says Lap-Band 2.0's PMA supplement approval 'huge'

13:51 EST Norfolk Southern strength attributed to activist speculation - Shares of Norfolk Southern are up about 4% to $234.04 in afternoon trading. Earlier, TheDeal.com speculated that "an activist could retain former Kansas City Southern CEO Patrick Ottensmeyer as a possible director and CEO candidate" at Norfolk Southern, contacts tell The Fly.

13:12 EST FDA reports certain ResMed masks recalled due to safety issue with magnets - The U.S. Food and Drug Administration is alerting patients, caregivers, and health care providers about AirFit and AirTouch mask models recalled by ResMed Ltd. "These masks are used with bilevel positive airway pressure, also known as Bilevel PAP, BiPAP, or BPAP, machines and continuous positive airway pressure, or CPAP. The recalled masks have magnets that can cause potential injuries or death when the magnets interfere with certain implanted metallic medical devices or metallic objects in the body. The FDA classified this recall as a Class I recall, the most serious type of recall," the agency stated in a notice. Reference Link

13:06 EST Panbela Therapeutics Inc trading resumes

13:01 EST Panbela Therapeutics Inc trading halted, volatility trading pause

12:32 EST Graham Holdings raises quarterly dividend 4% to $1.72 per share - Graham Holdings declared a regular quarterly dividend of $1.72 per share, payable on February 15, to shareholders of record on February 1. The dividend is a 4% increase from last quarter's $1.65 payout.

12:00 EST Humana falls -12.5% - Humana is down -12.5%, or -$56.15 to $391.61.

12:00 EST Fortuna Silver Mines falls -13.9% - Fortuna Silver Mines is down -13.9%, or -49c to $3.05.

12:00 EST Lifezone Metals rises 9.8% - Lifezone Metals is up 9.8%, or 61c to $6.84.

12:00 EST M.D.C. Holdings rises 18.2% - M.D.C. Holdings is up 18.2%, or $9.68 to $62.77.

11:31 EST Pressure BioSciences receives open order agreement for Nano-CBD Topical Spray - Pressure BioSciences announced the receipt of an Open Order Agreement for the purchase in 2024 of a minimum of 10,000 bottles of the Company's Nano-CBD Topical Spray, with an initial product shipment in the coming weeks, from the Company's west coast manufacturing partner. Subsequent shipments will follow quickly thereafter. VICAR Holdings has recently formed with a central health and wellness mission, focused on the on-line sale of only the highest quality and performance products, featured in a premium "PrescriptionGrade" product line. The company's website and online store are currently under construction, with the initial PrescriptionGrade products slated for Beta testing in March 2024, and fully launching into sales in Q2 2024. VICAR has proudly announced PBIO's Nano-CBD Topical Spray will be the first product available through their on-line store. The product will be sold as PrescriptionGrade Nano-CBD.

11:27 EST Outkick delivers monthly average of 7.2M total multiplatform unique visitors - OutKick finished 2023 with the most growth year over year amongst its competitive set in total multiplatform unique visitors, delivering a monthly average of 7.2 million total multiplatform unique visitors, up 65% versus 2022, according to Comscore. Additionally, OutKick saw increases across all categories in the fourth quarter of 2023 versus 3Q 2023 with 73 million total multiplatform views, 73 million total multiplatform minutes, and 6.1 million total multiplatform unique visitors, according to Comscore. In commenting on the digital performance, OutKick founder Clay Travis said,"2023 was a tremendous year for OutKick. We've added new shows, top-tier talent, and most importantly continued to generate engaging content with a roster that's unfiltered and fearless." To close out the year, OutKick saw 341 million total multiplatform views and 368 million total multiplatform minutes. The platform also finished with strong increases in social engagement on Facebook, X (formerly Twitter), and Instagram with 13.8 million social actions, up 119% year over year and Facebook, X, and YouTube with over 1 billion video views, up 987% versus 2022, according to Shareablee.

11:23 EST Deciphera presents long-term follow-up results from INTRIGUE Phase 3 trial - Deciphera Pharmaceuticals announced the presentation of new long-term results from the INTRIGUE Phase 3 clinical study comparing QINLOCK versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. The presentation titled "Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: final analyses from INTRIGUE" will be presented by John Zalcberg, M.D., Ph.D., Cancer Research Program, Monash University School of Public Health and Preventive Medicine and Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Results of INTRIGUE Study Long-Term Follow-Up: In INTRIGUE, 453 patients in the all-patient intent-to-treat population with second-line GIST were randomized 1:1 to receive QINLOCK 150 mg once daily or sunitinib 50 mg once daily of which 444 patients received treatment. In the primary analysis of the AP-ITT population based on a data cut of September 1, 2021, while the primary endpoint was not achieved, QINLOCK demonstrated similar efficacy with a median progression-free survival of 8.0 months versus 8.3 months for sunitinib. There were fewer patients with Grade 3/4 drug-related treatment emergent adverse events with QINLOCK compared with sunitinib. Based on the primary results from the INTRIGUE study, QINLOCK was included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for GIST as a preferred second-line regimen for patients with advanced GIST who are intolerant to sunitinib . The final analysis includes 18 months of additional follow up after the primary analysis based on a data cut of March 15, 2023. Key highlights from the final results presented include the following: Overall Survival: There were 211 OS events in the AP-ITT population with median duration of follow-up in the QINLOCK and sunitinib arms of 35.1 months and 34.1 months, respectively. Median OS in the AP-ITT population was similar with QINLOCK versus sunitinib. Safety and Tolerability: Among the 444 patients treated, 9.0% of patients remained on treatment at the time of data cutoff including 12.6% of 223 patients treated with QINLOCK and 5.4% of 221 patients treated with sunitinib. The long-term safety profile of QINLOCK was consistent with the primary analysis. Fewer patients had Grade 3/4 drug-related TEAEs with QINLOCK versus sunitinib. Dose interruptions and reductions as well as treatment discontinuations due to TEAEs were lower with QINLOCK versus sunitinib. Fewer patients discontinued treatment due to any TEAE for QINLOCK versus sunitinib. The most common TEAEs in the QINLOCK arm were alopecia, fatigue, and myalgia. The most common TEAEs in patients treated with sunitinib were palmar-plantar erythrodysesthesia syndrome, diarrhea, and hypertension. Exploratory Analysis: Efficacy of Next-Line Therapy: Median PFS on the next line of therapy after protocol treatment was similar for QINLOCK (7.7 months) versus sunitinib in the AP-ITT population. Following study treatment discontinuation, the most common third-line therapy was sunitinib for patients in the QINLOCK arm and regorafenib for patients in the sunitinib arm. Patients in the QINLOCK arm who received third-line sunitinib had a median PFS on next line of therapy of 8.5 months compared with 6.3 months for patients in the sunitinib arm who received third-line regorafenib.

10:09 EST FirstEnergy subsidiary submits School Bus Pilot Program proposal to Maryland PSC - FirstEnergy Corp. subsidiary Potomac Edison has submitted a five-year Electric School Bus Pilot Program proposal to the Maryland Public Service Commission intended to help the state reach its climate goals, the company announced. "The pilot supports Maryland's Climate Solutions Now Act of 2022, which requires any new school buses contracted or purchased by public school systems in the state to be zero emissions," the company stated.

10:00 EST Direxion Daily Semiconductor Bull 3X Shares rises 8.7% - Direxion Daily Semiconductor Bull 3X Shares is up 8.7%, or $2.48 to $30.91.

10:00 EST M.D.C. Holdings rises 18.0% - M.D.C. Holdings is up 18.0%, or $9.54 to $62.63.

10:00 EST Fortuna Silver Mines falls -9.3% - Fortuna Silver Mines is down -9.3%, or -33c to $3.21.

09:47 EST Fortuna Silver Mines falls -7.9% - Fortuna Silver Mines is down -7.9%, or -28c to $3.26.

09:47 EST Humana falls -11.9% - Humana is down -11.9%, or -$53.13 to $394.62.

09:47 EST LiveRamp rises 11.1% - LiveRamp is up 11.1%, or $4.10 to $41.01.

09:42 EST Mountain Crest Acquisition Corp IV trading resumes

09:35 EST Birkenstock Holdings PLC trading resumes

09:33 EST Peltz says promises Iger made when rejoining Disney board 'have not been kept'

09:31 EST Lexeo Therapeutics Inc trading halted, volatility trading pause

09:30 EST Birkenstock Holdings PLC trading halted, volatility trading pause

09:30 EST Cosmos Health completes acquisition of ten-drug portfolio - Cosmos Health has completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for EUR 3.2 million, or approximately $3.5 million at today's exchange rate. This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio. The selected drugs have been chosen for their efficacy in addressing a variety of health issues, including treatments for diabetes, cholesterol, respiratory, and cardiac conditions, among other critical health areas. This diverse selection underlines Cosmos Health's unwavering commitment to providing diverse medical needs through comprehensive, patient-centric healthcare solutions, catering to the specific needs of patients across multiple medical domains. All medicines will be manufactured at the facilities of the Company's wholly-owned subsidiary, Cana Laboratories.

09:21 EST Sekisui House to acquire M.D.C. Holdings for $4.9B in all-cash transaction - Sekisui House and M.D.C. Holdings announced a definitive agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash transaction with an equity value of $4.9B. Subject to and in accordance with the terms and conditions of the agreement, MDC shareholders will receive $63.00 per share in cash, which represents an approximately 19% premium to MDC's closing stock price on January 17, 2024, the last trading day prior to announcing the transaction, and an approximately 41% premium to MDC's 90-day volume-weighted average trading price. Closing of the acquisition is expected in the first half of 2024, subject to certain conditions, including approval of the merger by MDC's stockholders, regulatory approvals and other customary conditions. The transaction is not subject to a financing condition. Larry Mizel and David Mandarich and certain of their respective affiliates and estate planning vehicles, who beneficially own approximately 21.2% of MDC's shares, have entered into an agreement, among other things, to vote in favor of the transaction subject to and in accordance with the terms and conditions set forth therein.

09:19 EST Disney needs to invest more in parks, competition getting 'keener,' Peltz says - Trian's Nelson Peltz is being interviewed on CNBC to discuss his proxy fight with Disney for representation on the company's board.

09:16 EST Trian's Peltz 'loves' Disney, 'saddened' board didn't welcome his help - Trian's Nelson Peltz is being interviewed on CNBC to discuss his proxy fight with Disney for representation on the company's board.

09:06 EST Grove Collaborative appoints Scott Giesler as General Counsel - Grove Collaborative Holdings announced the appointment of Scott Giesler as General Counsel. Joining the executive leadership team, Mr. Giesler will report to Jeff Yurcisin, Chief Executive Officer. In this position, Mr. Giesler will oversee the Company's overall legal function

09:04 EST Sinclair Broadcast and NCTC announce renewal of long-term distribution agreement - Sinclair announced that it has renewed its distribution agreement with the National Content & Technology Cooperative a not-for-profit corporation whose members serve one-third of all broadband and video connected households in the U.S. and its territories The agreement allows NCTC's member companies to opt into a multi-year retransmission consent agreement for Sinclair's owned/operated local stations. The renewal also includes an agreement for Sinclair-owned Tennis Channel. NCTC represents almost 700 cable and broadband operators in all 50 states, and negotiating carriage agreements with content providers is among the many services it provides. "We are pleased to renew our agreement with NCTC, keeping our local broadcast stations and Tennis Channel available to the many independent cable system operators across the country, who provide a vital function, often serving the rural and underserved communities across the US," said Will Bell, Sinclair's SVP and Head of Distribution and Network Relations.

09:03 EST Edible Garden receives OSHA grant from Michigan OSHA - Edible Garden has received a grant from the Michigan Occupational Safety and Health Administration. The goal of the program is to create a safer and healthier work environment and reduce the risk of injury and illness to workers in Michigan.

09:02 EST Kelso Technologies' KIQ X Industries establishes Phase-One production facility - Kelso Technologies reports that its wholly owned subsidiary KIQ X Industries is establishing an initial Phase-One production facility with additional leased space at its current research and development facility in West Kelowna, BC, Canada. This Phase-One production facility is being designed and tooled to convert different classes of heavy duty "host" vehicles with the Company's patents pending proprietary Automated Traction Optimization Method for Vehicle Suspension Systems. These vehicles are targeted to be sold to customers operating in extreme terrain environments who have specified their custom user case requirements utilizing the Company's Method technologies. Once completed the Phase-One facility is expected to have a production capacity potential to facilitate approximately $25 million of annual revenue commencing in late 2024. With the assistance of the landlord, the current facility can be scaled to meet long term production volumes to service in excess of $100 million per year at the same location. The facility will house R&D, Phase-One production and an on-site test track.

09:01 EST Syra Health announces $480,000 contract from Indiana Department of Health - Syra Health announced a one-year, $480,000 contract from the Indiana Department of Health to administer public health and healthcare readiness assessments. Under the agreement, Syra Health's public health experts will be evaluating how existing hazards and risks impact public health, public health infrastructure, and behavioral health within the state of Indiana.

08:48 EST Verisk Analytics announces MSP Navigator on Duck Creek Content Exchange - Verisk announced MSP Navigator is the latest Verisk product to be made available on Duck Creek's Content Exchange. MSP Navigator provides casualty insurers with an efficient solution for Section 111 reporting, and they can benefit from the advanced automated reporting and analytical capabilities of the platform, facilitating compliance and avoiding civil monetary penalties. Verisk's proprietary platform offers a simple, effective method to identify Medicare beneficiaries for timely and accurate reporting of ongoing responsibility for medical treatment, settlements, judgments, awards, or other payments to the Centers for Medicare & Medicaid Services as required by Section 111 of the Medicaid & Medicare SCHIP Extension Act of 2007.

08:46 EST PodcastOne renews agreement with 'Our Fake History' podcast - PodcastOne has renewed the exclusive sales and distribution rights for Our Fake History podcast. The bi-weekly podcast enters its 9th season and in addition to historically educational original programming will also feature releases of fan favorite classic episodes. Our Fake History is set to air its 200th episode in March of this year.

08:44 EST BRP announces changes to Powersports and Marine organizational structures - BRP announces some changes to its Powersports and Marine organizational structures aiming at maximizing efficiencies and operational excellence, while leveraging its leaders' expertise to better position the Company for long-term growth. The Powersports and Marine Groups are combined under one leadership to ensure stronger alignment and focus, create synergies and enable the teams to leverage functional expertise stemming from both commercial businesses. This change further solidifies BRP's dedication to driving sustained profitable growth while delivering a compelling value proposition to its network of dealers and distributors. Sandy Scullion, currently President, Powersports Group, is appointed to the position of President, Powersports and Marine. In this position, Scullion will assume P&L responsibility for both businesses with direct oversight on Global Retail and Services. With his 30 years of experience at BRP, Scullion is a seasoned and visionary leader who has a deep understanding of the business and the market globally. Furthermore, to maximize efficiencies and elevate operational excellence, BRP is combining the Manufacturing Operations for the Powersports and Marine Groups under the leadership of Patrick Dussault. Dussault, who was already leading the manufacturing operations for Powersports, is therefore appointed to the position of Executive Vice-President, Global Manufacturing Operations, Powersports and Marine. As a result, Dussault becomes a member of the Executive Leadership Team of BRP. Since taking over the leadership of the Marine Group back in 2023, Bernard Guy made significant strides in positioning the business for success, namely by raising the bar to ensure the production facilities are ready to manufacture high-quality boats and pontoons. Guy is now refocusing on his primary role as Executive Vice-President, Global Product Strategy, Powersports and Marine.

08:41 EST Talphera announces $26M capital commitment - Talphera announced a total of $26M of committed capital including $8M from a partial monetization of DSUVIA royalties and milestones, $6M of equity issued at a first closing, $10M of committed capital upon the announcement of positive NEPHRO registration trial data, and an additional $2M if Talphera stock trades above a specified price following the NEPHRO registration trial announcement. The equity issuance transaction with Nantahala Capital and Rosalind Advisors totals $18M, with $6M at the first closing, $10M at the second closing upon Talphera announcing the achievement of the NEPHRO registration trial's primary endpoint and a statistically significant secondary endpoint of mean post-filter activated clotting time composed of measurements made in the first 72 hours, and an additional $2M should Talphera stock trade at a price of at least 92c per share for 5 days after the announcement of the NEPHRO registration trial data. At closing, expected on January 19 Abhinav Jain of Nantahala Capital Management will join Talphera's Board of Directors, further strengthening Talphera's Board. Talphera will issue 7,792,208 pre-funded warrants in lieu of shares to purchase common stock at a price of 76.9c per share at the first closing of the transaction. The warrants will have an exercise price of 0.1c per share, for a total purchase price per share of common stock of 77c. Talphera expects to issue 12,987,013 pre-funded warrants in lieu of common stock at a price of 76.9c per share at a second closing upon the achievement of the Pivotal Trial Milestone, and 2,597,403 pre-funded warrants in lieu of common stock at a price of 76.9c per share upon the achievement of the Price Milestone. In addition, Talphera will amend certain Series A common stock warrants to purchase up to 2,941,178 shares of common stock and certain Series B common stock warrants to purchase up to 2,941,178 shares of common stock previously issued to Nantahala and Rosalind in July 2023, to lower the exercise price of such warrants to $0.77 per share. The total additional capital available to the Company should all outstanding Series A and Series B common stock warrants be exercised is $14.4M. Talphera has completed a partial monetization of its DSUVIA royalties and milestones with XOMA for $8M. Talphera expects the committed funding to provide sufficient capital to fund Talphera through a potential approval of Niyad, targeted in the first half of 2025. Talphera expects the top-line data read-out of its NEPHRO registration trial in the third quarter of 2024, with an expected pre-market approval application submitted before the end of 2024. Talphera preliminary cash balance at the end of 2023 totaled approximately $9.4M. Cash operating expenses, or selling, general and administrative, and research and development expenses, excluding stock-based compensation, is expected to be in the range of $21M-$23M in 2024, which includes the initiation and expected completion of the NEPHRO registration trial during the year.

08:41 EST LQR House announces marketing partnership featuring Pinaq Spirits - LQR House announces a new collaboration with Pinaq, a spirits brand, starting on February 1, 2024. The goal of this strategic partnership is to amplify awareness and generate sales on LQR House's ecommerce marketplace. This is achieved as the Company directs all marketing campaigns to its website, CWSpirits.com.

08:39 EST Signing Day announces schedule for 2024 U.S. Army Bowl National Combine Series - Signing Day Sports announced an extensive schedule of events as National Recruiting Partner for the 2024 U.S. Army Bowl National Combine Series as part of its ongoing extensive collaboration with The U.S. Army Bowl. The U.S. Army Bowl National Combine Series, encompassing 21 events over the next five months, will showcase the skills of over 4,000 emerging student-athletes. Student-athlete participation in the combines is required for selection for the iconic 2024 U.S. Army Bowl game. With an anticipated turnout of at least 200 student-athletes at each combine, these events will not only provide participants recruitment exposure and prospects, but also promote the Signing Day Sports app directly to many new users. All participants will be given access to the app's capabilities, advantages, and growing ecosystem to aid in their recruiting and development.

08:38 EST Adial Pharmaceuticals appoints Goodman as Chief Operating Officer - Adial Pharmaceuticals announced the appointment of Tony Goodman as Chief Operating Officer. A highly accomplished pharmaceutical industry executive and member of Adial's Board of Directors since 2017, Goodman will oversee the Company's strategic growth initiatives, including clinical development and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the area of addiction treatment. He will continue to serve on Adial's Board.

08:37 EST LM Funding mined 108 bitcoin in three months ended December 31 - Funding America provided a preliminary, unaudited Bitcoin mining update for the three and twelve months ended December 31, 2023. Bruce Rodgers, Chairman and CEO of LM Funding, stated, "We continue to make steady progress in our Bitcoin mining operations. In the fourth quarter alone, we mined 108.0 Bitcoin. Over the same time period, the Company sold 103.0 Bitcoin, generating approximately $3.4 million in proceeds. We continue to strategically reinvest the proceeds of our Bitcoin sales back into the business as we position the Company for the upcoming Bitcoin halving event anticipated to occur during the first half of 2024."

08:37 EST Surrozen sees cash runway into 2025 - $43.4 million in cash, cash equivalents, and marketable securities as of September 30, 2023 resulting in cash runway into 2025

08:35 EST Surrozen prioritizes development of SZN-043 for alcohol-associated hepatitis - SZN-043 is the first development candidate using Surrozen's SWEETS technology. Surrozen is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. The Company expects to announce safety and pharmacodynamic data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024. The company anticipates enrolling patients with alcohol-associated hepatitis in a Phase 1b clinical trial in 2024 and expects that proof-of-concept data from this trial may be available in the second half of 2024.

08:35 EST Doherty Enterprises acquires 21 Applebee's restaurants in NY City metro area - Doherty Enterprises announced it has acquired 21 Applebee's restaurants located throughout the New York City metro area. The deal marks a significant strategic move, as Doherty expands its footprint in the restaurant franchise market. The Allendale, NJ-based company has been an Applebee's franchisee since 1993, and today owns and operates 104 Applebee's restaurants in New York, New Jersey, Florida, and Georgia. Through this acquisition, Doherty now ranks 25th in Top 200 Franchisees in the United States by Restaurant Finance Monitor with a portfolio of 160 franchise restaurants across New York, New Jersey, Florida, and Georgia including Applebee's, Panera Bread, and Chevys Fresh Mex. They additionally own two restaurant concepts, Shannon Rose Irish Pub and Spuntino Wine Bar, and operate a combined four restaurants under these two brands.

08:33 EST Intelligent Bio Solutions announces Robinson Brothers using IFDS system - Intelligent Bio Solutions announced that Robinson Brothers, one of the UK's largest independent chemical manufacturers, is now using its revolutionary portable Intelligent Fingerprinting Drug Screening, IFDS, System to support its drug and alcohol testing policy, "As a 24/7 manufacturing operation, Robinson Brothers clearly appreciated the flexibility that sweat-based drug testing provides, giving the HR team the ability to screen employees whenever they need to," added Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. "What's clear is that our portable, non-invasive system takes the complexity out of workplace drug testing and is increasingly replacing traditional workplace testing methods using urine and saliva."

08:32 EST Meiwu Technology regains compliance with Nasdaq listing requirements - Meiwu Technology announced on January 9, 2024, it received notice from the NASDAQ Office of General Counsel that the bid price deficiency of Meiwu's ordinary shares has been cured, and Meiwu has regained compliance with NASDAQ Marketplace Rule 5550(a)(2). As a result, a previously scheduled hearing with the NASDAQ Hearing Panel has been deemed moot and will not be held. Meiwu's ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.

08:31 EST Blink Charging, McArthurGlen partner for EV chargers - Blink Charging is teaming up with McArthurGlen to provide visitors to the Netherlands-based designer outlet centers, Roermond and Roosendaal, with EV charging as they shop. The two designer outlet communities in the South of the Netherlands attract millions of visitors annually. The Roermond designer outlet has 70 EV Chargers, which will grow to 400 in the next two years, while the Roosendaal designer outlet has 19 EV Chargers, which will grow by six more this year.

08:24 EST Incannex completes dosing, therapy in Phase 2 PsiGAD trial - Incannex Healthcare has completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial, the Company's Phase 2 study evaluating its own psilocybin treatment program for patients with generalized anxiety disorder/ PsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial. The primary objective of the study is to determine whether a 7-week program of psilocybin-assisted psychotherapy for GAD is superior to active placebo-assisted psychotherapy in decreasing symptoms of GAD, as measured by the change in the Hamilton Anxiety Rating Scale from baseline to week 11. Safety and tolerability were assessed, as well as other secondary objectives of efficacy and quality of life. Incannex commenced the process of drafting an FDA IND application in August 2023 in preparation of the receipt of topline results from the PsiGAD-1 clinical trial, and submission soon thereafter.

08:22 EST Bausch Health, Solta announce NMPA approval of Thermage FLX, TR-4 Return Pad - Bausch Health and Solta Medical announced the approval of Thermage FLX and the TR-4 Return Pad by China's National Medical Products Administration. The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration. Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface to optimize a patient's appearance.

08:21 EST Mace Security appoints Kunal Mehta as head of digital marketing - Mace Security International announced the appointment of Kunal Mehta as its new Head of Digital Marketing. In this role, Mr. Mehta will be responsible for overseeing the Company's entire digital marketing strategy and direct-to-consumer growth strategies. Mehta has held previous executive roles including CEO of Punchey, Inc., a privately held VC-backed payment business servicing small and medium enterprises primarily in the automotive industry

08:17 EST Allstate Q4 estimated catastrophe losses $68M, pre-tax - The Allstate Corporation announced fourth quarter estimated catastrophe losses, prior year reserve reestimates and implemented rates. Allstate's estimated catastrophe losses were below the $150M reporting threshold for December 2023. Total catastrophe losses for the fourth quarter were $68M, pre-tax. Unfavorable prior year reserve reestimates, excluding catastrophes, totaled $199M in the fourth quarter, with approximately $148M related to personal auto, including costs for claims in litigation. During the month of December, the Allstate brand implemented auto rate increases of 16.5% across 15 locations, resulting in total brand premium impact of 5.0%, which includes the rate increases approved in December by the Departments of Insurance in California, New York and New Jersey. "Allstate continued to make progress on our comprehensive plan to improve profitability. In 2023, rate increases for Allstate brand auto insurance resulted in a premium impact of 16.4%, which are expected to raise annualized written premiums by approximately $4.27B and rate increases for Allstate brand homeowners insurance have resulted in a premium impact of 11.3%, which are expected to raise annualized written premiums by approximately $1.16B," said Jess Merten, Chief Financial Officer of The Allstate Corporation.

08:16 EST Osisko Mining turns power on at Windfall site - Osisko Mining provided the following corporate updates on the Corporation's activities for 2024. The 85 km long 69 kV hydro-electric power line built, owned and operated by the Waswanipi Cree First Nation has been completed on schedule, and grid power has successfully been connected to the Windfall Project. The use of hydroelectricity at the Windfall Project marks the switching over from diesel generated electricity to operate the camp and underground infrastructure and will significantly reduce both power costs and greenhouse gas emissions at the site. Osisko has begun a 35,000 meter drill program on the Urban-Barry properties as part of its 70% earn-in option with Bonterra Resources/ The program will initially focus on the Moss showing, located five kilometres south-west along strike from the Windfall gold deposit, where an historical intercept of high-grade mineralization in prior Bonterra drilling has been interpreted by Osisko's exploration team to potentially represent the Lynx mineralized system seen at the Windfall Project. Regional exploration also continues on Windfall Mining Group's claim package with an additional 30,000 metres of drilling targeting potential gold-bearing structures including the extension of the Bank fault and porphyritic intrusions associated with favorable alterations. The Windfall Environmental Impact Assessment review process by the COMEX is ongoing, and the Corporation is expecting WMG to receive the first round of questions in the coming months. In parallel, the Corporation expects to finalize the Windfall Impact and Benefits Agreement with the Cree First Nation of Waswanipi and the Cree Nation Government in 2024.

08:13 EST Lightspeed announces new partnership with GreatLIFE - Lightspeed Commerce announced a new partnership with GreatLIFE Golf & Fitness, an industry-leading Multi-Course Operator, MCO. Through this partnership Lightspeed will provide courses in GreatLIFE's portfolio with custom technology solutions that are tailored to their unique operational needs. Powering the world's best businesses, Lightspeed is the unified POS and payments platform for ambitious entrepreneurs who wish to accelerate growth, provide the best customer experiences and become a go-to destination in their space. The collaboration marks a milestone in the golf technology landscape and highlights Lightspeed's continued commitment to providing cutting-edge solutions for the golf industry. "We are thrilled to welcome GreatLIFE Golf & Fitness into the Lightspeed family," said David Hope, General Manager, Lightspeed Golf. "Our two organizations share a commitment to providing flexible, innovative solutions to the golf industry that empower owners and operators. It's through this commitment that we saw a natural alignment. With this partnership in place, it marks a step forward in our shared vision for accessible, technology-driven golf experiences."

08:13 EST Genasys announces Los Angeles County agreed to 5-year contract - Genasys announced that Los Angeles County has agreed to a 5-year contract that expands Genasys Protect EVAC utilization across the entire county to reduce evacuation time and improve speed of relaying public information to impacted areas. "Our leading-edge, unique evacuation management solution is a revolutionary step in public safety." said Richard Danforth, CEO of Genasys. "Within the last few years, 36 of California's 58 counties have adopted Genasys Protect EVAC and we are committed to the success of LA County."

08:11 EST Star Equity announces KBS Builders signed $2M contract for Nantucket project - Star Equity Holdings announced that its KBS Builders business has signed a $2M contract to manufacture 14 modular units to provide seasonal workforce housing for the Town of Nantucket, MA. These modular units will be used to construct a multi-family building consisting of 20 apartments, offering affordable housing to those who live and work on the island. KBS expects to begin manufacturing these units in March, with delivery to be completed by May. Rick Coleman, CEO of Star Equity, noted, "We are thrilled to start the year with the signing of another large affordable housing contract for KBS. Following the announcement of our $1.9 million affordable housing project in Maine in late 2023, this new contract further demonstrates KBS' essential role in supporting local governments and communities to address challenges related to housing shortages, especially affordable workforce housing. Our KBS team has worked diligently to expand its capabilities and continues to be a major modular player in the New England area."

08:09 EST Korro Bio presents new data for KRRO-110, reported portfolio progress - Korro Bio presented new data for KRRO-110 and reported progress across its RNA editing portfolio at the J.P. Morgan Healthcare Conference on January 9, 2024. Pipeline updates: KRRO-110: As announced on December 7, 2023, Korro selected KRRO-110 as its first development candidate for the potential treatment of AATD, an inherited genetic disorder caused by single nucleotide variants in the SERPINA1 gene. Preclinical data to date for KRRO-110 demonstrated: High specificity with no bystander effects in MZ human primary hepatocytes; Intravenous administration at 2 mg/kg resulted in secretion of ~50microM functional AAT as early as 7 days post-single dose in a human transgenic PiZ mouse model; Increase in AAT protein and the inhibition of elastase activity were sustained through week 9 when dosed every 2 weeks, demonstrating durability in mice; Greater than 40% editing in NHPs utilizing an earlier generation oligonucleotide designed to edit a surrogate SERPINA1 RNA target site; Preclinical development of KRRO-110 is ongoing in preparation for a regulatory filing expected in the second half of 2024, with a potential interim clinical readout in the second half of 2025. Platform Update: Korro's proprietary RNA editing platform, OPERA, integrates a deep understanding of adenosine deaminase acting on RNA (ADAR) enzymology with expertise in oligonucleotide chemistry, machine learning optimization of oligonucleotides and fit-for-purpose delivery. CHORDs, or Customized High-fidelity Oligonucleotides for RNA Deamination, are single-stranded, anti-sense oligonucleotides designed to have high target efficiency and specificity by leveraging the pillars of OPERA. Creating De Novo Mutation to Alter Protein Function: In addition to repairing pathogenic SNVs, CHORDs can be used to engineer de novo SNVs and change amino acids on proteins to endow them with desired altered properties while still preserving their broader functional capabilities. In preclinical studies, Korro has demonstrated the ability to: Activate a transcription factor in an undisclosed target ; Demonstrated activation of a transcription factor by creating a de novo protein variant resulting in sustained downstream activity in NHPs lasting longer than 21 days, demonstrating potential to preserve transcription factor function; Selectively modulate TDP-43 to reduce protein aggregation ; TDP-43 is a protein associated with ALS, FTD and other neurodegenerative diseases. A single RNA edit to TDP-43 is predicted to lead to the synthesis of a protein variant that does not aggregate, thereby preserving normal function and protecting downstream activity essential for neuronal health; Modulate ion channels to within physiological levels in Nav1.7 ; Nav1.7 is a voltage-gated sodium channel that is essential for pain sensation and electrical signaling in the central nervous system. Korro has demonstrated that site-specific changes are sufficient to decrease the activity of Nav1.7. This approach has the potential to deliver potent analgesic activity without the dose-limiting toxicities that have been observed by sodium channel blockers

08:08 EST NeuroBo announces pre-clinical safety data of DA-1241 with sitagliptin - NeuroBo Pharmaceuticals announced positive pre-clinical safety data of DA-1241, a novel G-Protein-Coupled Receptor 119, or GPR119, agonist, in combination with sitagliptin, a DPP4 inhibitor. Additionally, having satisfied its 45-day commitment with the FDA related to its amended protocol, the company has opened enrollment for Part 2 of its Phase 2a clinical trial of DA-1241 when co-administered with sitagliptin for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. The pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone, DA-1241 alone, or sitagliptin in combination with DA-1241 for 13 weeks, was well tolerated with no adverse effects. Each of the two-parts of the Phase 2a trial of DA-1241 is designed to be a 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical study to evaluate the efficacy and safety of DA-1241 in subjects with presumed MASH. Part 1, currently dosing subjects, is exploring the efficacy of DA-1241 versus placebo, and is expected to enroll approximately 49 subjects, who will be randomized in a 1:2:1 ratio into 3 treatment groups: DA-1241 50 mg, DA-1241 100 mg, or placebo. Part 2 will explore the efficacy of DA-1241 in combination with sitagliptin, versus placebo, is expected to enroll approximately 37 subjects, who will be randomized in a 2:1 ratio into 2 treatment groups: DA-1241 100 mg/sitagliptin 100 mg or placebo.

08:07 EST Akoya Biosciences' PhenoCycler-Fusion platform used by QSBC - Akoya Biosciences announced that the newly established Queensland Spatial Biology Centre, QSBC, located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated. The PhenoCycler-Fusion platform facilitates the understanding of the cellular compositions, neighborhoods, and functional states that are present in complex diseases, and that next generation therapeutics may be able to target. Bringing a new level of clarity to this complex biology will help explain why individual patients have varying degrees of success in terms of their response to treatment. "We are extremely excited to be an integral part of this important initiative," said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. "The QSBC has brought together a remarkable group of researchers, clinicians, pathologists, and computational biologists who are unrelenting in their commitment to leverage the enormous power of spatial biology. Their passion is inspiring and we look forward to supporting them with the most advanced spatial biology solutions."

08:07 EST Morgan Stanley still sees getting to 30% wealth margin, CEO says on CNBC - CEO Ted Pick tells CNBC that the company sees mid-20% wealth margins for awhile.

08:06 EST Vail Resorts sees FY24 Resort Reported EBITDA in lower half of guidance range - Commenting on the ski season-to-date, Kirsten Lynch, CEO said, "Given the challenging conditions to start the 2023/2024 North American ski season, we are pleased with our season-to-date results and the guest service delivered at our resorts, highlighting the stability provided by our season pass program and the investments we have made in our resorts and employees. Through the holiday period ended January 7, 2024, conditions across our North American resorts were below average in all regions compared to the strong early season conditions in the prior year period, leading to a decline in both local and destination skier visitation. The unfavorable conditions impacted all of our North American resorts, and particularly our Eastern U.S. (comprising the Midwest, Mid-Atlantic and Northeast) and Tahoe resorts, which were impacted by limited natural snow and variable temperatures that resulted in delayed openings, reduced terrain offerings, and select resort closure days through the holiday period. Although the conditions negatively impacted visitation across our North American resorts, particularly among our local guests, our season pass sales results significantly mitigated the impact of the slower start to the season on overall lift revenue and highlight the stability created by our advance commitment strategy. Despite the decline in season-to-date visitation relative to the prior year period, we are pleased with the strength in ancillary spending per visit across our ski school, rental, and dining businesses." Lynch continued, "As a result of the challenging conditions through the holiday period, season-to-date guest visitation and revenue was below our expectations in North America. The majority of our North American resorts experienced significant snowstorms leading up to and over the Martin Luther King Jr. holiday weekend, which impacted the guest experience, but also led to recently improved conditions across our resorts. Based on our significant base of pre-committed guests through advance commitment pass products and an improvement in conditions across our resorts in recent weeks, we now expect that Resort Reported EBITDA for fiscal 2024 will be in the lower half of the guidance range issued on September 28, 2023. Our guidance assumes a continuation of the improvement in conditions that we are currently experiencing at our North American resorts, normal weather conditions for the remainder of the 2023/2024 European ski season and the 2024 Australian ski season, a continuation of the current economic environment, and the foreign currency exchange rates as of our original September 2023 guidance. We are looking forward to the remainder of the season given the recently improved conditions, the investments we have made to continue elevating the guest experience, and the stability provided by our season pass program."

08:05 EST Hunch Technologies to be public through Direct Selling Acquisition combination - FlyBlade, or Hunch Mobility, a provider of urban air mobility in the Indian subcontinent, has entered into a definitive business combination agreement with Direct Selling Acquisition (DSAQ), a special purpose acquisition company, and certain other parties thereto. Upon the closing of the transaction, the newly combined company is expected to be called Hunch Technologies, and its common shares are expected to be listed on the New York Stock Exchange under the symbol (HNCH). The combined company is expected to have an estimated post-transaction enterprise value of $223M, assuming no redemptions by DSAQ's public stockholders. Proceeds from the transaction, before the payment of certain transaction expenses, will comprise up to $63M of cash held in DSAQ's trust account before redemptions, with approximately $48M in net cash on the balance sheet to fund growth, assuming no redemptions by DSAQ's public stockholders. The transaction does not include a minimum cash condition, but does include capital commitments of $20M from investor. Investor's $20M investment includes $10M of equity purchases in DSAQ previously made in the open market subject to non-redemption, $3M in the form of promissory notes convertible into convertible preferred shares to be funded in three equal monthly installments, with the first $1M promissory note being issued at signing, and $7M of convertible preferred shares that will be funded at the closing of the transaction. Hunch Ventures has committed to investing $3M in the form of convertible preferred shares of PubCo. Hunch Ventures' investment and Investor's investments other than convertible notes are subject to certain waivable conditions. DSAQ and Hunch Mobility's respective boards of directors have unanimously approved the transaction, which is expected to close in 2024, subject to regulatory and stockholder approvals. In connection with the transaction, Hunch Mobility's shareholders are rolling 100% of their existing equity in Hunch Mobility into the combined company and are expected to own approximately 52% of the combined company on a non-fully diluted basis immediately following the closing of the transaction, assuming no redemptions by DSAQ's public stockholders. All references to cash on the balance sheet, available cash from the trust account and retained transaction proceeds are subject to any redemptions by DSAQ's public stockholders and current estimates of transaction expenses. For additional information regarding the terms of the transaction, as well as an investor presentation, please see the Current Report on Form 8-K, which will be filed today with the Securities and Exchange Commission, or SEC, by DSAQ. Additional information about the transaction will be provided in the registration statement on Form F-4 relating to the transaction to be filed with the SEC by PubCo.

08:04 EST aTyr Pharma announces appointment of Frederick as advisor - aTyr Pharma announced the appointment of Wayne Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.

08:03 EST Vaxxinity announces collaboration on space medicine research with UCF - Vaxxinity announced a collaboration with the University of Central Florida, UCF, to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. "If humanity is to become a spacefaring species, solving fundamental problems related to space travel and living are table-stakes. Vaxxinity is all-in on developing and commercializing these solutions, and working with the State of Florida and UCF, collectively, we strive to promote both healthy aging and ensure humanity can become multi-planetary, brave low gravity exposure, and be of the stars," says Lou Reese, Executive Chairman of Vaxxinity. "The support for this research from the State of Florida exemplifies a commitment to pioneering solutions in the fields of space travel, as well as longevity and age-related diseases."

08:02 EST Ceridian enters definitive agreement to acquire eloomi - Ceridian announced it has entered into a definitive agreement to acquire eloomi, a leading learning experience platform software provider based in Copenhagen, Denmark, and Orlando, Florida. The acquisition is expected to close in Q1 2024 and will be funded with existing balance sheet cash. "The dynamic learning and development needs of today's boundless workforce require leading enterprise solutions. The acquisition of eloomi will help supercharge the people development capabilities of Dayforce, equipping customers with more engaging learning and development experiences, AI-driven content creation, and extended enterprise learning capabilities," said Joe Korngiebel, Chief Product and Technology Officer, Ceridian. eloomi's all-in-one, modern learning platform offers the power of a compliance-driven LMS together with the benefits of a leading Learning Experience Platform. It provides leading learning and development capabilities to more than 850 customers around the world.

07:46 EST Equifax extends relationship with the NCTUE - Equifax has extended its long-standing relationship with the National Consumer Telecom and Utilities Exchange, or NCTUE, an independent, non-profit, Fair Credit Reporting Act-compliant consumer credit reporting agency for the telecommunications, pay TV, internet, home security and utility industries. Under the terms of the extended agreement, Equifax will continue its exclusive operation and management of the NCTUE database, and provide the organization with enhanced product innovation, advanced data security measures, and marketing support for new member recruitment. The extended service agreement is subject to the oversight of the NCTUE board of trustees.

07:41 EST Nextech3D.AI says search engine able to deliver 500% increase in productivity - Nextech3D.ai announces its recently launched AI 3D model search engine can deliver up to a 500% increase in the production of 3D models, which is a marked increase from its previously announced 80% increase in productivity. The Company plans on releasing its AI search engine to the public in Q1 2024 for general use and charging on a per use basis which could contribute significantly to the Company's growth in 2024.

07:38 EST Ranchero Gold enters agreement for sale of Paika's interest in four licenses - Ranchero Gold announced that further to its press release of December 27, 2023, its wholly-owned subsidiary Minera y Metalurgia Paika has entered into a definitive agreement dated January 17, 2024 with Minas de Oro Nacional, a wholly-owned subsidiary of Alamos Gold, for the sale of Paika's interest in four mineral licenses comprising an area of 5,390 hectares of the Company's Santa Daniela mineral property located in Sonora, Mexico. The Company intends to relinquish its interest in the remaining portions of the Santa Daniela property in order to eliminate holding costs. The Disposition is subject to the approval of the TSX Venture Exchange and the shareholders of the Company. In relation to the Disposition, Ranchero has convened a special meeting of its shareholders to be held on February 22, 2024, to seek shareholder approval for the Disposition. The Company has solicited voting support agreements from shareholders holding a total 44,483,247 common shares of the Company or 67.67%, of the outstanding Common Shares, confirming their intention to vote in favor of the Disposition. In connection with the Disposition, the Company has agreed, subject to the approval of the TSXV, to pay a finder's fee to an arm's length party to the Company and Alamos, equal to 5% of the net proceeds or consideration received by the Company and Paika under the Definitive Agreement, being C$333,300. The Finder facilitated the introduction of the Company to Alamos and the discussions between the parties in negotiating the terms of the Disposition. The Finder's Fee will be payable 50% in cash and 50% in Common Shares at a minimum price of C$0.03 per Common Share for up to 5,555,000 Common Shares. The Finder's Fee will be payable in stages based on the consideration received by Paika under the Definitive Agreement, with the first tranche payable once the cash payment in the amount of $1,892,000 is received by Paika under the terms of the Definitive Agreement. The Common Shares issuable to the Finder will be subject to a four-month hold period from the date of issuance in accordance with applicable securities laws.

07:31 EST Agrify enters into first hydrocarbon extraction lab, VFU facility in California - Agrify Corporation announced it has entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park, a California-based vertically integrated cannabis operator. Ocean Deep will be extracting products with Agrify's turnkey PX30 Hydrocarbon Extraction Lab Package to bolster its product offerings. Ocean Deep is also expected to begin operation with an estimated 120 Vertical Farming Units, VFU, sold by the Company to produce high-quality cannabis flower in 2024. Raymond Chang, Chairman and CEO of Agrify, shared that "We are very excited to announce this agreement for the sale of our first combined VFU and PX30 Hydrocarbon Extraction Lab facility in the state of California. We applaud our partner Ocean Deep/Golden Lake Business Park's foresight for selecting Agrify's technologies in the fiercely competitive California market. We believe our superior cultivation and extraction technologies will allow Ocean Deep to offer the highest quality and most consistent products to its customers."

07:22 EST Microbot adds U.S.-based Clinical Research Associate ahead of IDE submission - Microbot Medical announced that following the recent results of its pivotal GLP Pre-Clinical Study, and to support its anticipated IDE submission to commence its first in human clinical trial, the Company added a US- based Clinical Research Associate. The CRA will join the already established clinical team in the USA, led by Dr. Juan Diaz-Cartelle, the Company's Chief Medical Officer.

07:21 EST Boeing announces Akasa Air orders 150 more 737 MAX jets - Boeing and Akasa Air announced the Indian carrier has placed a follow-on 737 MAX order, confirming 150 more jets in its order book. The purchase of 737-10 airplanes and additional 737-8-200 jets by India's all-737 operator was revealed at the Wings India 2024 airshow. "Akasa Air will leverage the 737 MAX family to expand its domestic and international network in the coming years. Since launching operations in 2022, the airline has captured approximately 4% of India's domestic market, serving 18 destinations with a fleet of 22 737 MAX jets," Boeing stated. "We are excited to announce this historic order for 150 new Boeing airplanes, increasing our total orders from Boeing to 226 jets. In addition to supporting our rapid domestic expansion, the efficiency and economics of these new airplanes position Akasa to launch international routes in the coming months. The lower carbon emissions of the 737 MAX family allow us to remain focused on sustainable operations, while also providing our environmentally conscious passengers with a more comfortable way to fly. Sustainability is at the core of our business, and we strive for more opportunities to reduce our impact to the environment," said Vinay Dube, Akasa Air founder and CEO. Reference Link

07:13 EST Castle study shows DecisionDx -SCC test to guide radiation in cSCC reduces cost - Castle Biosciences announced the publication of a new study1 in The Journal of Clinical and Aesthetic Dermatology JCAD which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could result in substantial Medicare healthcare savings of up to approximately $972M annually. "The implications of this study are significant, as evidenced by the opportunity to save our overburdened healthcare system hundreds of millions of dollars through use of the DecisionDx-SCC test to guide more risk-appropriate utilization of ART in patients with SCC," said Ally-Khan Somani, M.D., Ph.D., lead author, director of Mohs micrographic, reconstructive surgery & cutaneous oncology at SkinMD LLC, and adjunct clinical assistant professor, Department of Dermatology & Otolaryngology-Head and Neck Surgery at Indiana University School of Medicine. "Above and beyond the considerable cost savings is the potential to truly improve SCC patient care by using the test's results to provide added confidence in decisions to forgo radiation therapy when a patient's risk of metastasis is low."

07:09 EST Humana falls 11% to $399.75 after lowering FY23 adjusted EPS outlook

07:08 EST Humana sees 2024 individual Medicare Advantage growth of 100,000 members - In a regulatory filing, Humana stated, "Based on the results of the annual election period, Humana now expects individual Medicare Advantage growth of approximately 100,000 members for the year ending December 31, 2024, representing 1.8 percent growth over its membership as of December 31, 2023 of approximately 5.4 million members, compared to its previous commentary of 'at or slightly above industry average growth'. The company's membership growth outlook for 2024 is impacted by its balanced approach to pricing which resulted in a lower share of overall industry growth. While the company's overall AEP sales volume was in line with expectations, a higher proportion was driven by plan change activity by existing members, resulting in lower new member sales than expected. Despite the higher plan change activity, the company experienced slightly higher attrition during the AEP than expected. Actual AEP growth for the company is approximately 120,000 members, which is expected to decline slightly by year end due to the more limited sales opportunity post AEP and the expectation that the company will see slightly higher attrition within its Dual Special Needs Plan offerings over the next several months as members lose dual eligible status from the on-going Medicaid redetermination process. The company continues to believe it took a prudent approach to 2024 pricing considering the current regulatory changes and evolving utilization environment. In addition, the company believes it remains well positioned to compete as an industry leader in the attractive Medicare Advantage market going forward with its differentiated capabilities, including highly diversified and patient centered value-based care arrangements, exceptional quality as demonstrated by its industry leading Stars scores, best in class consumer experience rankings, and continued growth and integration of its CenterWell capabilities."

07:08 EST HilleVax appoints McLoughlin as Chief Operating Officer - HilleVax (HLVX) announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Lead, RSV at GSK (GSK).

07:05 EST Orthofix enters pact with MRIguidance to distribute BoneMRI imaging software - Orthofix announced it has entered into an agreement with MRIguidance to distribute its BoneMRI imaging software in the U.S. The company also announced the completion of the world's first eight cases utilizing BoneMRI software with 7D's Flash Navigation System. BoneMRI creates a synthetic CT from an MRI imaging exam without the use of harmful radiation. For the first time, surgeons, their staff, and patients can now benefit from completely radiation-free preoperative imaging and spinal navigation using BoneMRI with the 7D FLASH Navigation System.

07:04 EST Orezone Gold reports Q4 gold production 33,916 ounces - Orezone Gold announced 2023 gold production results and connection of the Bombore Mine to the national grid.Q4 and Full Year 2023 Production Results: Gold production totalled 33,916oz during the fourth quarter, and 141,425oz for the full year 2023, achieving annual guidance of 140,000 to 155,000oz. Gold sales during the quarter were 33,782oz at an average realized price of $1,997/oz, resulting in sales of $67.5M. For the full year, gold sales totaled 139,696oz at an average realized price of $1,940/oz, resulting in sales of $271.0M. Patrick Downey, President & CEO stated, "With a strong Q4, the Bombore mine had a successful first full year of operations and achieved guidance, which is a testament to the hard work and dedication of our operating team. Operational performance was matched by a strong safety record, with no lost-time injuries in 2023. I am also very pleased to report that construction of the Bombore powerline was completed on-schedule in late December. Commissioning and acceptance by the state power provider SONABEL to bring power to site commenced in early January and has now been completed. Process plant energization is in progress and will be completed by January 21, 2024. The powerline replaces the use of onsite diesel gensets for power, significantly lowering our operating costs and carbon footprint." Early works for the Bombore Phase II expansion commenced in the fourth quarter of 2023. These activities included: ordering of the SAG mill, early-stage engineering, and bulk earthworks on the hard rock mill site. Discussions with our senior lender, Coris Bank, are ongoing and the Company expects to receive a financing proposal later in the first quarter.

07:02 EST Clearlake sold its remaining shares of Janus International Group - Clearlake Capital Group announced that the Firm sold its remaining shares of Janus International Group and fully exited its investment in December. Janus is a global manufacturer and supplier of turn-key building solutions and access control technologies for the self-storage, commercial, and industrial sectors. Clearlake acquired Janus in February 2018 in partnership with the founding management team and remained its largest shareholder when Janus listed on the NYSE in June 2021. Under Clearlake's ownership, the Company executed several initiatives, including but not limited to the development of new access control technologies and the purchase and integration of seven acquisitions.

06:52 EST Fastenal expects reduced closing activity in 2024 - The company stated, "Our in-market network forms the foundation of our business strategy. In recent years, we have seen a gradual increase in our in-market locations because of significant growth in Onsites and, to a lesser degree international branches, which has more than overcome a meaningful decline in our traditional branch network. In any period, the number of locations closed tends to reflect normal churn in our business, whether due to redefining or exiting customer relationships, the shutting or relocation of customer facilities that host our locations, or a customer decision, as well as our ongoing review of underperforming locations. We will continue to open or close locations to sustain and improve our network, support our growth drivers, and manage our operating expenses. However, we believe the strategic rationalization that has produced the meaningful decline in our traditional branch network in the United States and Canada since 2013 is largely completed, and we expect reduced closing activity beginning in 2024."

06:45 EST KeyCorp sees FY24 NII down 2%-5% vs. FY23 - Sees FY24 noninterest income up 5%+ with upside if capital activity normalizes. Sees relatively stable noninterest expense vs. FY23, net charge-offs 30-40bps, and a GAAP tax rate of 20%.

06:42 EST EU car market experienced 3.3% decline in December, ACEA reports - In December 2023, the EU car market experienced a 3.3% decline, recording 867,052 units in sales, reported the ACEA. "This drop can be attributed to the high baseline performance in December 2022. December also marked the first month of contraction after 16 consecutive months of growth," the industry group stated. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

06:20 EST Masimo says Federal Circuit lifts stay on Apple Watch import ban - Masimo (MASI) said it welcomes the Federal Circuit's ruling to lift the temporary stay on the import ban of certain Apple Watch (AAPL) models. This decision reinstates the U.S. International Trade Commission's import ban and cease and desist order on Apple watches that were found to infringe Masimo's patented pulse oximetry technology, the company said in a statement. 'The Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry," said Joe Kiani, Founder and CEO of Masimo. "It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others' patents." Reference Link

06:17 EST Origin Agritech appeals Nasdaq delisting letter - Origin Agritech announced that it has submitted an appeal to Nasdaq's Listing Qualifications Department to request a further extension of time and present its plan to regain compliance with Nasdaq Listing 5550. The company is committed to maintaining its Nasdaq listing and is confident it can meet continuing listing compliance. The requested appeal stays any delisting or suspension action pending the issuance of a final decision by Nasdaq. The company is also working on completing its annual report on Form 20-F as soon as possible.

06:16 EST Nuvve Holding announces 1-for-40 reverse stock split - Nuvve Holding announced that it will effect a 1-for-40 reverse stock split of its common stock, to be effective as of January 19. Nuvve's common stock will begin trading on a split-adjusted basis commencing upon market open on Monday, January 22.

06:10 EST Goodyear Tire announces Mark Stewart as CEO - Goodyear Tire (GT) announced that Mark Stewart has been elected CEO and president, effective January 29. He will succeed Richard Kramer, who previously announced his planned retirement from the company following 24 years of service, including 14 as chairman, CEO and president. On the effective date, Laurette Koellner, independent lead director of Goodyear's board since 2019, will become non-executive board chair, and Stewart will be added to the Goodyear board as a director. Stewart joins Goodyear from Stellantis (STLA), where he served as COO of North America and a member of the group executive council.

06:08 EST TSMC sees FY24 capital budget $28B-$32B

05:24 EST Argenx announces MHLW approval for Vyvdura injection in Japan - Argenx announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, approved Vyvdura injection for subcutaneous use for the treatment of adult patients with generalized myasthenia gravis, or gMG, who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies, or ISTs. Following this decision, Vyvgart is now approved in Japan for both intravenous and self-administered SC use.

05:17 EST Rackspace Technology, Google Cloud AI enable BMG to process royalties faster - Rackspace Technology (RXT) has announced it has helped enable service enhancements for artists and songwriters signed to music company BMG. Using Google Cloud's (GOOGL) advanced AI and big data capabilities, BMG can process royalty payments ten times faster and track music 50% faster. The achievement stems from Rackspace Technology's Elastic Engineering team successfully migrating 95% of BMG's applications and services to Google Cloud. BMG's new cloud-based platform will also support new data tools it will use following its decision to take control of its previously outsourced distribution, striking direct deals with streaming platforms such as Spotify and Apple. Faced with a consistent 30% annual increase in the data intake and to address these complexities, BMG strategically pivoted to Google Cloud, recognizing the need for enhanced tools such as AI, Google Kubernetes Engine and BigQuery to manage burgeoning data volumes and optimize operational efficiency effectively.

05:07 EST Fortuna Silver Mines reports Q4 gold equivalent production 136,154 ounces - Fortuna Silver Mines reported production results for the fourth quarter and FY23 from its five operating mines in Latin America and West Africa. For FY23, Fortuna produced a record 326,638 ounces of gold and 5,883,691 ounces of silver or a record 452,389 gold equivalent ounces, including lead and zinc by-products. For Q4 the company reported record gold equivalent production of 136,154 ounces; a 6% increase compared to Q3 2023. Reported record gold production of 107,376 ounces; a 13% increase compared to Q3 2023 and silver production of 1,354,003 ounces; a 19% decrease compared to Q3 2023.